Press "Enter" to skip to content

ImmunoGen drug fails cancer study, shares slide 40 pct

U.S. drug developer ImmunoGen Inc said on Friday its experimental ovarian cancer drug failed to meet the main goal of a late-stage study, driving its shares more than 40 percent lower on Friday.

Original source:

Also Read:   Bristol-Myers Squibb buying Celgene in USD 74 bn deal